NiKang Therapeutics Funding: $260M Raised, Series C (2021)
NiKang Therapeutics is based in Wilmington, Delaware. It has raised $260M in total funding. Latest round: Series C.
NiKang Therapeutics funding overview
NiKang Therapeutics is based in Wilmington, Delaware. NiKang Therapeutics has raised $260M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series C announced in May 2021. The round record for NiKang Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include Cormorant Asset Management, HBM Healthcare Investments, Octagon Capital Advisors, EcoR1 Capital, Perceptive Advisors, Wellington Management and 15 others. 21 distinct backers are named across the disclosed rounds.
NiKang Therapeutics at a glance
Total raised
$260M
Latest round
Series C
Latest round date
May 2021
Headquarters
Wilmington, Delaware
Notable investors
Cormorant Asset Management, HBM Healthcare Investments, Octagon Capital Advisors, EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital
Frequently asked about NiKang Therapeutics funding
How much has NiKang Therapeutics raised?
NiKang Therapeutics has raised $260M in total disclosed funding across the rounds on record.
Who has invested in NiKang Therapeutics?
Cormorant Asset Management, HBM Healthcare Investments, Octagon Capital Advisors, EcoR1 Capital, Perceptive Advisors, Wellington Management are named among the investors backing NiKang Therapeutics.
What was the latest NiKang Therapeutics funding round?
The most recent disclosed round is a Series C, announced in May 2021.
Where is NiKang Therapeutics based?
NiKang Therapeutics is based in Wilmington, Delaware.
When did NiKang Therapeutics last raise?
The last disclosed NiKang Therapeutics round closed in May 2021 at Series C.
Totals shown for NiKang Therapeutics aggregate every disclosed round on file. To see how that compares, browse the companies in Wilmington and the investors behind them below.
